MedTrace Logo

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

NCT03276728 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2022-08-08

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).

Conditions

Interventions

DRUG

AMG 986 IV

AMG 986 solution for infusion

DRUG

AMG 986 PO

AMG 986 tablets for oral (PO) administration

DRUG

Placebo PO

Matching placebo tablets for oral administration

DRUG

Placebo IV

Matching placebo solution for infusion

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-12
Primary Completion
2019-04-18
Completion
2019-04-18
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • France
  • Germany
  • Netherlands
  • New Zealand
  • Poland
  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03276728 on ClinicalTrials.gov